NFKB1 and colorectal cancer: To the best of our knowledge, this is the first report that the second-generation proteasome inhibitor, carfilzomib, which is more selective with better effects and lower toxicity than first generation proteasome inhibitors, is an effective antitumor agent that significantly enhanced the CPT-11 chemosensitivity of colorectal cancer through inhibition of multiple NF-κB related mechanisms, and could be a potential novel therapeutic for treating colorectal cancer patients.